University Of Michigan Rogel Cancer Center

This study tests a powerful mix of hormone therapy, a targeted drug (niraparib), and precise radiation in men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach can keep PSA levels low for three years. About 100 men are p…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vo…

This early-phase trial tests whether adding the drug mycophenolate mofetil (MMF) to radiation therapy is safe for people with glioblastoma, an aggressive brain cancer. About 68 participants with newly diagnosed or recurrent glioblastoma will receive MMF alongside radiation. The m…

This study tests whether giving higher, precisely targeted radiation to the most aggressive parts of a glioblastoma brain tumor can help people live longer. About 30 adults with newly diagnosed glioblastoma will receive this advanced radiation therapy along with the standard chem…

This study tests a new drug called APG-115, alone or with chemotherapy, in people with a specific type of salivary gland cancer that has a normal p53 gene. The goal is to see if the drug can shrink tumors and to find the safest dose. The trial includes 41 adults whose cancer has …

This study tests a new treatment for men with prostate cancer that has spread to a few other places in the body. The treatment combines targeted radiation with hormone therapy and a drug called olaparib. The goal is to see if this approach can stop the cancer from growing for at …

This study looks at whether a special gene test can help men with low-risk prostate cancer safely choose active surveillance (watching the cancer closely) instead of immediate treatment like surgery or radiation. About 800 men with early-stage prostate cancer are taking part. The…

This study tests whether combining two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the drug combi…

This study tests whether an 8-week virtual music-based relaxation program can help reduce anxiety in adolescent and young adult cancer survivors aged 15-39. Participants will practice relaxation skills for 45 minutes each week. The goal is to see if the program is practical and h…

This study looks at whether certain women with early-stage breast cancer can skip radiation after a lumpectomy. The participants are postmenopausal, have hormone receptor-positive, HER2-negative tumors, and a low Oncotype DX score. They will take hormone therapy but no radiation,…